Colesevelam hydrochloride: Usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol

European Journal of Preventive Cardiology

Volumn 16, Issue 1, 2009, Pages 1-9

  Corsini, Alberto ^a   Windier, Eberhard ^b   Farnier, Michel ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Point Medical   (France)

Author keywords

bile acid sequestrant; cardiovascular disease; colesevelam hydrochloride; lipid lowering; low density lipoprotein cholesterol; nonsystemic drug

Indexed keywords

ALLYLAMINE; COLESEVELAM; DRUG DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID SEQUESTRANT; COLESTIPOL; COLESTYRAMINE; DIGOXIN; ETHINYLESTRADIOL; EZETIMIBE; FENOFIBRATE; GLIBENCLAMIDE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE; METFORMIN; METOPROLOL; MEVINOLIN; NICOTINIC ACID; NORETHISTERONE; PIOGLITAZONE; PRAVASTATIN; QUINIDINE; REPAGLINIDE; SIMVASTATIN; SULFONYLUREA; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; WARFARIN;

BLOOD; DRUG INTERACTION; HUMAN; HYPERCHOLESTEROLEMIA; REVIEW; ABDOMINAL CRAMP; ADD ON THERAPY; AREA UNDER THE CURVE; ATHEROSCLEROSIS; BLOATING; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE SEQUENCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; FAMILIAL HYPERCHOLESTEROLEMIA; FECES IMPACTION; FILM COATING; FLATULENCE; GASTROINTESTINAL SYMPTOM; KIDNEY CLEARANCE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TABLET FORMULATION; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DRUG INTERACTIONS; HUMANS; HYPERCHOLESTEROLEMIA;

EID: 65649114360     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e32831215db     Document Type: Review

References (54)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–1278.
2. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis J Am Coll Cardiol 2005; 46: 1855–1862; Epub 24 Oct 2005.
3. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–1504.
4. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, et al Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005; 46: 1405–1410.
5. Erhardt LR, Gotto A Jr. The evolution of European guidelines: changing the management of cholesterol levels. Atherosclerosis 2006; 185: 12–20.
6. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 2004; 110: 227–239.
7. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al European guidelines on cardiovascular disease prevention in clinical practice: full text Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl 2): S1–S113.
8. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004; 43: 2142–2146.
9. Feldman T, Koren M, Insull W Jr, McKenney J, Schrott H, Lewin A, et al Treatment of high-risk patients with ezetimibe plus simvastatin coadministration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004; 93: 1481–1486.
10. Leiter LA, Rosenson RS, Stein E, Reckless JP, Schulte KL, Schleman M, et al Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 2007; 194: e154–e164.
11. Pisciotta L, Fasano T, Bellocchio A, Bocchi L, Sallo R, Fresa R, et al Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis 2007; 194: e116–e122.
12. Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, et al Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004; 148: 447–455.
13. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc Drugs Ther 2005; 19: 403–414.
14. Medical_Letter Colesevelam (Welchol) for hypercholesterolemia. Med Lett Drugs Ther 2000; 42: 102–104.
15. Melian EB, Plosker GL. Colesevelam. Am J Cardiovasc Drugs 2001; 1: 141–146. Discussion 147–148.
16. Davidson MH. The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin Pharmacother 2007; 8: 2569–2578.
17. Welchol (colesevelam hydrochloride) Product Information 2008 – 625 mg tablets – Initial U.S. Approval: 2000.
18. Holmes-Farley SR, Harry Mandeville W, Miller KL, Petersen J, Ward J, Sacchiero B, et al Colesevelam hydrochloride: synthesis and testing of a novel polymer gel pharmaceutical. Polymer Preprints 2000; 41: 735–736.
19. Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother 2003; 4: 779–790.
20. Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, et al Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999; 159: 1893–1900.
21. Einarsson K, Ericsson S, Ewerth S, Reihner E, Rudling M, Stahlberg D, Angelin B. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism Eur J Clin Pharmacol 1991; 40 (Suppl 1): S53–S58.
22. Wood PD, Shioda R, Estrich DL, Splitter SD. Effect of cholestyramine on composition of duodenal bile in obese human subjects. Metabolism 1972; 21: 107–116.
23. Braunlin W, Zhorov E, Smisek D, Guo A, Appruzese W, Xu Q, et al In vitro comparison of bile acid binding to colesevelam HCI and other bile acid sequestrants. Polymer Preprints 2000; 41: 708–709.
24. Steinmetz KL, Schonder KS. Colesevelam: potential uses for the newest bile resin. Cardiovasc Drug Rev 2005; 23: 15–30.
25. Aldridge MA, Ito MK. Colesevelam hydrochloride: a novel bile acid-binding resin. Ann Pharmacother 2001; 35: 898–907.
26. Donovan JM, Kisicki JC, Stiles MR, Tracewell WG, Burke SK. Effect of colesevelam on lovastatin pharmacokinetics. Ann Pharmacother 2002; 36: 392–397.
27. Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, et al Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001; 110: 352–360.
28. Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001; 158: 407–416.
29. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005; 44: 467–494.
30. Zetia Physician desk reference for ezetimibe. 58th edition. Montvale (New Jersey): Thomson PDR; 2004. pp. 2118–2123.
31. Bays H, Rhyne J, Abby S, Lai YL, Jones M. Lipid-lowering effects of colesevelam HCL in combination with ezetimibe. Curr Med Res Opin 2006; 22: 2191–2200.
32. Zema MJ. Colesevelam HCI and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am J Ther 2005; 12: 306–310.
33. Xydakis AM, Guyton JR, Chiou P, Stein JL, Jones PH, Ballantyne CM. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol 2004; 94: 795–797.
34. Jones MR, Baker BA, Mathew P. Effect of colesevelam HCL on single-dose fenofibrate pharmacokinetics. Clin Pharmacokinet 2004; 43: 943–950.
35. Donovan JM, Stypinski D, Stiles MR, Olson TA, Burke SK. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther 2000; 14: 681–690.
36. Cholestagel (colesevalm hydrochloride) Summary of Product Characteristics 2007 – 625 mg film-coated tablets.
37. Matsui MS, Rozovski SJ. Drug-nutrient interaction. Clin Ther 1982; 4: 423–440.
38. Vroonhof K, van Rijn HJ, van Hattum J. Vitamin K deficiency and bleeding after long-term use of cholestyramine. Neth J Med 2003; 61: 19–21.
39. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413–428.
40. Insull W Jr, Toth P, Mullican W, Hunninghake D, Burke S, Donovan JM, Davidson MH. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc 2001; 76: 971–982.
41. Davidson MH, Toth P, Weiss S, McKenney J, Hunninghake D, Isaacsohn J, et al Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 2001; 24: 467–474.
42. Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006; 97: 1198–1205.
43. Knopp RH, Tsunehara C, Retzlaff BM, Fish B, Nguyen H, Anderson S, Nguyen T. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. Metabolism 2006; 55: 1697–1703.
44. Rivers SM, Kane MP, Busch RS, Bakst G, Hamilton RA. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr Pract 2007; 13: 11–16.
45. McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin 2005; 21: 1403–1412.
46. Moore A, Phan B, Challender C, Williamson J, Marcinova S, Zhao X. Effects of adding extended-release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease. J Clin Lipidol 2007; 1: 620–625.
47. Rosenson RS. Colesevelam HCL reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis 2006; 185: 327–330.
48. Devaraj S, Autret B, Jialal I. Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia. Am J Cardiol 2006; 98: 641–643.
49. Claudel T, Staels B, Kuipers F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 2005; 25: 2020–2030.
50. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994; 121: 416–422.
51. Bays HE, Cohen DE. Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCL in patients with type 2 diabetes mellitus. Curr Med Res Opin 2007; 23: 1673–1684.
52. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. reduction in incidence of coronary heart disease. J Am Med Assoc 1984; 251: 351–364.
53. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, Piatt R. Discontinuation of antihyperlipidemic drugs – do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125–1131.
54. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J. Persistence of use of lipid-lowering medications: a cross-national study. J Am Med Assoc 1998; 279: 1458–1462.